CSIMarket
 


Neuropathix Inc.  (TYGS)
Other Ticker:  
 
 

TYGS's Free Cash Flow Growth by Quarter and Year

Neuropathix's Free Cash Flow results by quarter and year




TYGS Free Cash Flow (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December - -0.03 -0.14 0.11
III Quarter September - -0.14 -0.23 -0.70
II Quarter June - -0.27 -0.23 -0.70
I Quarter March -0.11 -0.45 -0.35 -0.70
FY   -0.11 -0.89 -0.95 -1.99



TYGS Free Cash Flow first quarter 2022 Y/Y Growth Comment
Neuropathix Inc. in the first quarter 2022 recorded free cash outflow of $ -0.11 millions.

According to the results reported in the first quarter 2022, Neuropathix Inc. achieved the best Free Cash Flow growth in Major Pharmaceutical Preparations industry. While Neuropathix Inc.' s Free Cash Flow no change of % ranks overall at the positon no. in the first quarter 2022.




TYGS Free Cash Flow ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Neuropathix's first quarter 2022 Free Cash Flow $ -0.11 millions TYGS's Income Statement
Neuropathix's first quarter 2021 Free Cash Flow $ -0.45 millions Quarterly TYGS's Income Statement
New: More TYGS's historic Free Cash Flow Growth >>


TYGS Free Cash Flow (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Free Cash Flow first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Free Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Free Cash Flow first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Free Cash Flow Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Free Cash Flow by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Neuropathix's Q/Q Free Cash Flow Growth


Free Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TYGS's I. Quarter Q/Q Free Cash Flow Comment
Recent results of -0.11 millions by Neuropathix Inc. appear even worse if you take a look at free cash outflow -0.03 millions a quarter before.

Within Major Pharmaceutical Preparations industry Neuropathix Inc. achieved highest sequential Free Cash Flow growth. While Neuropathix's Free Cash Flow growth quarter on quarter, overall rank is .


Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Free Cash Flow Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


TYGS's I. Quarter Q/Q Free Cash Flow Comment
I. Quarter 2022 accomplishment of -0.11 millions by Neuropathix Inc. look even more unfavourable considering the free cash outflow -0.03 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry Neuropathix Inc. achieved highest sequential Free Cash Flow growth. While Neuropathix's Free Cash Flow growth quarter on quarter, overall rank is .


Neuropathix's 12 Months Free Cash Flow Growth Year on Year


Free Cash Flow TTM Growth

12 Months Ending
(Mar 31 2022)
12 Months Ending
(Dec 31 2021)
12 Months Ending
(Sep 30 2021)
12 Months Ending
(Jun 30 2021)
12 Months Ending
(Mar 31 2021)
Cumulative Free Cash Flow 12 Months Ending $ -0.56 $ -0.89 $ -1.00 $ -1.08 $ -1.04
Y / Y Free Cash Flow Growth (TTM) - - - - -
Year on Year Free Cash Flow Growth Overall Ranking # # # # #
Seqeuential Free Cash Flow Change (TTM) - - - - -
Seq. Free Cash Flow Growth (TTM) Overall Ranking # # # # #




Cumulative Free Cash Flow growth Comment


Neuropathix Inc. achieved highest trailing twelve month year on year Free Cash Flow growth. While overall Free Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Free Cash Flow growth Comment


Neuropathix Inc. achieved highest trailing twelve month year on year Free Cash Flow growth. While overall Free Cash Flow growth ranking, remained unchanged compare to the previous quarter at no. .

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Free Cash Flow Growth
Major Pharmaceutical Preparations Industry Free Cash Flow Growth Trends and Statistics
Healthcare Sector Free Cash Flow Growth Statistics
Free Cash Flow Growth Trends for overall market
TYGS's Free Cash Flow Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Free Cash Flow Growth
Lowest Ranking Free Cash Flow Growth
Free Cash Flow Growth for TYGS's Competitors
Free Cash Flow Growth for Neuropathix's Suppliers
Free Cash Flow Growth for TYGS's Customers

You may also want to know
TYGS's Annual Growth Rates TYGS's Profitability Ratios TYGS's Asset Turnover Ratio TYGS's Dividend Growth
TYGS's Roe TYGS's Valuation Ratios TYGS's Financial Strength Ratios TYGS's Dividend Payout Ratio
TYGS's Roa TYGS's Inventory Turnover Ratio TYGS's Growth Rates TYGS's Dividend Comparisons



Companies with similar Free Cash Flow no change for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Free Cash Flow for the quarter ending Mar 31 2022
Bristol myers Squibb Company-0.31%$ -0.314 millions
Bio techne Corp-2.32%$ -2.321 millions
Edwards Lifesciences Corporation-2.40%$ -2.396 millions
Chemed Corporation-5.27%$ -5.275 millions
Moderna Inc -7.00%$ -7.001 millions
Idexx Laboratories Inc-7.81%$ -7.809 millions
Abcellera Biologics Inc -8.51%$ -8.513 millions
Steris Plc-8.58%$ -8.583 millions
Abiomed Inc -8.68%$ -8.676 millions
Utah Medical Products Inc-8.80%$ -8.802 millions
Amedisys Inc -9.96%$ -9.964 millions
Sotera Health Company-11.03%$ -11.026 millions
Royalty Pharma Plc-12.51%$ -12.513 millions
Ironwood Pharmaceuticals inc -12.99%$ -12.986 millions
Quidelortho Corp-14.43%$ -14.431 millions
Endo International Plc-17.44%$ -17.438 millions
Amneal Pharmaceuticals Inc -18.76%$ -18.757 millions
Fulgent Genetics Inc -19.20%$ -19.199 millions
Medpace Holdings Inc -19.30%$ -19.301 millions
Bruker Corporation-20.61%$ -20.612 millions
Abbott Laboratories-21.69%$ -21.691 millions
Lemaitre Vascular Inc -22.44%$ -22.440 millions
Zoetis Inc -22.75%$ -22.750 millions
Gilead Sciences Inc -29.50%$ -29.502 millions
Globus Medical Inc -29.70%$ -29.700 millions
Hca Healthcare Inc -32.34%$ -32.344 millions
U S Physical Therapy Inc-34.09%$ -34.090 millions
Quest Diagnostics Inc-34.34%$ -34.337 millions
Carlisle Companies Incorporated-34.47%$ -34.467 millions
Integra Lifesciences Holdings Corp-35.81%$ -35.809 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com